tiprankstipranks
Denali Therapeutics (DNLI)
NASDAQ:DNLI
US Market
DNLI
Denali Therapeutics
RESEARCH TOOLSreports
Want to see DNLI full AI Analyst Report?

Denali Therapeutics (DNLI) Income Statement

880 Followers

Denali Therapeutics Income Statement

Last quarter (Q4 2025), Denali Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Denali Therapeutics's net income was $-128.55M. See Denali Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 330.53M$ 108.46M$ 48.66M
Gross Profit
$ -11.18M$ 0.00$ 330.53M$ 108.46M$ 48.66M
Operating Expenses
$ 544.16M$ 487.34M$ 527.23M$ 449.21M$ 344.41M
Depreciation and Amortization
$ 14.81M$ 8.99M$ 16.73M$ 10.38M$ 8.59M
EBITDA
$ -497.63M$ -492.89M$ -179.97M$ -330.36M$ -287.16M
Operating Income
$ -555.34M$ -487.34M$ -196.70M$ -340.74M$ -295.75M
Other Income/Expenses
$ 42.90M$ 64.64M$ 51.51M$ 14.77M$ 4.59M
Pretax Income
$ -512.44M$ -422.70M$ -145.19M$ -325.97M$ -291.16M
Net Income
$ -512.54M$ -422.77M$ -145.22M$ -325.99M$ -290.58M
Per Share Metrics
Basic EPS
$ -2.97$ -2.57$ -1.06$ -2.60$ -2.39
Diluted EPS
$ -2.97$ -2.57$ -1.06$ -2.60$ -2.39
Weighted Average Shares Outstanding
 175.46M 164.47M 137.37M 125.53M 121.52M
Weighted Average Shares Outstanding (Diluted)
 175.46M 164.47M 137.37M 125.53M 121.52M
Currency in USD

Denali Therapeutics Earnings and Revenue History